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Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used to treat migraine, but the mechanisms of their effects in this
pathology are not fully elucidated. The trigeminal ganglia and calcitonin gene-related peptide (CGRP) have been implicated in the
pathophysiology of migraine. The release of CGRP and prostaglandin E2 (PGE2) from freshly isolated rat trigeminal ganglia was
evaluated after oral administration of nimesulide, etoricoxib, and ketoprofen, NSAIDs with different pharmacological features.
Thirty minutes after oral administration, nimesulide, 10mg/Kg, decreased the GCRP release induced by an inflammatory soup,
while the other NSAIDs were ineffective at this point in time. Two hours after oral nimesulide (5 and 10mg/Kg) and ketoprofen
(10mg/Kg), but not of etoricoxib, a significant decrease in the CGRP release was observed. All drugs reduced PGE2, although
with some differences in timing and doses, and the action on CGRP does not seem to be related to PGE2 inhibition. The
reduction of CGRP release from rat trigeminal ganglia after nimesulide and ketoprofen may help to explain the mechanism of
action of NSAIDs in migraine. Since at 30 minutes only nimesulide was effective in reducing CGRP release, these results suggest
that this NSAID may exert a particularly rapid effect in patients with migraine.1. Introduction
Migraine is a very common and disabling neurological disor-
der, with a complex pathophysiology that has not yet been
fully understood. In current hypotheses, migraine-specific
triggers cause a primary brain dysfunction, which causes
dilation of cranial blood vessels innervated by trigeminal
fibers [1]. The dilated blood vessels mechanically activate
perivascular trigeminal sensory fibers to release vasoactive
peptides such as substance P and calcitonin gene-related pep-
tides (CGRP). These and other peptides further increase
vasodilation and produce neurogenic inflammation, leakage
of blood vessels, and mast cell activation [2]. CGRP is a 37
amino acid neuropeptide widely expressed within the ner-
vous system both centrally and peripherally in every site thathas been implicated in migraine: meninges, trigeminal gan-
glia, spinal cord trigeminocervical complex, brainstem
nuclei, and cortex [3, 4]. In the trigeminal vascular system
(the portions of the trigeminal nerve that innervate cerebral
and meningeal blood vessels), more than 50% of trigeminal
neurons express CGRP [5]. Upon stimulation, this peptide
is released from the neuronal cell bodies in the trigeminal
ganglia and at the nerve endings, where it mediates vasodila-
tion via smooth muscle cell receptors and plasma extravasa-
tion [6]. Isolated trigeminal ganglia release CGRP both
basally, and in response to noxious stimuli and to inflamma-
tory mediators, with a rapid response [5]. CGRP and CGRP
receptors are also present centrally, where the peptide may
participate in central sensitization [7]. Although there are
several other peptides and factors coreleased by trigeminal
2 Mediators of Inflammationnociceptor endings, CGRP is recognized as crucial in the
pathophysiology of migraine [8]. New compounds that target
CGRP or its receptor have been increasingly explored in
recent years as new treatments for migraine [4, 8, 9].
About half of migraine patients recur to over-the-counter
medications to treat their acute attacks instead of getting pro-
fessional advice on available specific treatments [10], and
nonsteroidal anti-inflammatory drugs (NSAIDs) are still
largely used to treat migraine [11]. Although NSAIDs have
been used clinically for many years, and it is well known that
their effects involve inhibition of the two cyclooxygenases
(COX-1/-2) expressed throughout the body, it is not clear
which mechanism, apart from the established inhibition of
prostaglandin synthesis, defines their different clinical pro-
files, which are highly relevant for the treatment of migraine
in patients. Comparative studies between NSAID effects in
headache or migraine models are only few [12, 13]. In partic-
ular, very little is known about the effect of NSAIDs on CGRP
in the trigeminal vascular system, but some recent evidence
indicate that both nonselective and COX-2-selective inhibi-
tors in vitro are able to block CGRP release from cultured
TG cells [13]. The objective of our experimental study was
to evaluate whether different NSAIDs modulate trigeminal
CGRP basal and induced release, an action that would be
highly significant in the control of migraine. At the same
time, we were interested in testing the possible relation
between the inhibition of prostaglandin E2 (PGE2) synthesis
and that of CGRP release in trigeminal ganglia (TG). To this
purpose, we tested the effect of in vivo administration of
nimesulide, ketoprofen, and etoricoxib, 3 NSAIDs with dif-
ferent selectivity for COX-1/-2 on the release of CGRP and
PGE2 from rat TG, in basal conditions and during stimula-
tion with an artificial inflammatory soup. Freshly isolated
TG, where trigeminal sensory neurons are still within their
natural environment of supportive cells, are considered the
most suitable preparation for the purpose of our study.
2. Materials and Methods
2.1. Animals. Sprague Dawley male adult rats (weight 250–
300 g) were purchased from Envigo, Italy and housed with
light/dark cycles for 12 hours, temperature of 22± 2°C,
humidity of 55± 10%, and food and water ad libitum. After
at least 1 week of acclimation, the animals were randomly
assigned to the different treatments. They were sacrificed fol-
lowing total anesthesia according to European Community
Council Directive 86/609/EEC on the ethical use of animals,
following protocols according to the guidelines of the Com-
mittee for Research and Ethical Issues of the International
Association for the Study of Pain. Experimental procedures
and research project were approved by local institutional ani-
mal care and use committee.
2.2. Drugs and Treatments.Nimesulide, a preferential COX-2
inhibitor, was obtained by Helsinn Healthcare SA (Lugano,
Switzerland); ketoprofen, a NSAID with a high COX-1 inhi-
bition activity, and etoricoxib, a selective COX-2 inhibitor,
were purchased from Sigma (Milan, Italy). Drugs were dis-
solved in water, sonicated while stirring immediately beforeadministration, and delivered by oral gavage (per os) in a vol-
ume of 1ml/Kg. Control animals were treated with the same
volume of vehicle (water) only. Animals were then returned
to their individual cage with free access to food and water.
Animals were monitored to ensure the absence of any treat-
ment regurgitation, which is however unlikely in the rat. All
drugs were administered at the doses of 10mg/Kg, 5mg/Kg,
and 1mg/Kg. These doses were chosen on the basis of the
previous literature data that showed a significant anti-
inflammatory activity in rat models [14–16]. Either 30
minutes or 2 hours after oral NSAID administration, animals
were sacrificed with CO2 for trigeminal ganglia collection.
2.3. Trigeminal Ganglia Isolation and Preparation. Trigemi-
nal ganglia were rapidly dissected with a standardized proce-
dure taking between 5 and 7 minutes. The meninges were
removed, and each ganglia was chopped into 4 pieces of
1.5–2mm thickness in Ca2+-free PBS at room temperature,
to facilitate diffusion of CGRP and PGE2 released from tri-
geminal cells. Chopped ganglia were then rinsed for 5
minutes with oxygenated Dulbecco’s Modified Eagle’s
medium (DMEM, no serum and no glutamine added) at
37°C in an Eppendorf tube of 1.5ml volume, which was
exchanged 5-6 times. This tissue preparation was chosen
after preliminary experiments, as it proved to represent a
good compromise to keep as intact as possible the ganglionic
architecture and at the same time improve the release of
PGE2 and CGRP into the extracellular solution. After rinsing,
a 0.5ml volume of DMEM was added to the ganglia and
placed in a CO2 incubator at 37
°C. After 5 minutes, the
supernatant was removed after gentle stirring and used for
measuring basal release. Medium was immediately replaced
with 0.5ml of an artificial inflammatory soup (IS): 10μM
serotonin, 10μM histamine, 10μM bradykinin, 25mM KCl,
and 10μM capsaicin, dissolved in DMEM. After 5 minutes
and a final gentle stirring, supernatant was removed. Basal
and IS samples were centrifuged to remove small debris
and immediately split in 2 aliquots, one was immediately
stored at −80°C for PGE2 quantitation, while the other one
was diluted with 25μl of 10x EIA buffer from the CGRP
EIA Kit. No reliable CGRPmeasurement could be performed
if samples did not contain EIA buffer before freezing. Also,
these samples were then stored at −80°C before analysis.
2.4. CGRP and PGE2 Assays. CGRP and PGE2 were evaluated
with commercially available EIA assay kit (SpiBio cat. num-
ber A05482 and Cayman cat. number 514010, resp.). Sensi-
tivities of the assays were 1 pg/ml for CGRP and 15 pg/ml
for PGE2.
2.5. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism 5 Software (San Diego, CA, USA).
Data were tested for equal variance and for normal distribu-
tion before choosing statistical tests. Analysis was performed
with one way ANOVA. If an overall test comparing groups
was significant, Bonferroni test was used for between-group
comparisons in the post hoc analysis. The overall significance
level was 0.05 for each hypothesis. Each group consisted of 6
animals. Data are mean± SEM.
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Figure 1: (a) Effect of oral administration of 10mg/Kg nimesulide, ketoprofen, etoricoxib, or water on CGRP release from trigeminal ganglia
after in vitro stimulation with inflammatory soup (IS). Thirty minutes and 2 hours after administration, rats were sacrificed, trigeminal
ganglia were collected and maintained in vitro with DMEM alone for 5 minutes, then medium was collected, and ganglia were stimulated
with IS for another 5 minutes. CGRP released in media basally and upon stimulation was measured by EIA. CGRP levels are
expressed as % of basal values (measured before addition of IS) that were normalised to 100. Values are mean± SEM of 6 animals.
∗p < 0,05; ∗∗∗p < 0,001 versus basal; °p < 0,05; °°p < 0,01; °°°p < 0,001 versus water + IS. (b) Dose-dependent inhibition of CGRP release
in vitro by trigeminal ganglia after stimulation with IS by nimesulide, ketoprofen, and etoricoxib. Rats were treated orally with NSAIDs at
the doses of 10, 5, and 1mg/Kg. Two hours after administration, rats were sacrificed, and experiment was carried on as in (a). Values are
mean± SEM of 6 animals. ∗∗p < 0,01; ∗∗∗p < 0,001 versus basal; °p < 0,05; °°°p < 0,001 versus water + IS.
3Mediators of Inflammation3. Results
Rats were treated orally with nimesulide, ketoprofen, etor-
icoxib, or water, and 30 minutes or 2 hours after adminis-
tration, TG were dissected and isolated as described in
Methods. TG were rinsed in Dulbecco’s Modified Eagle’s
medium at 37°C, then were allowed to rest for 5 minutes
in a 500μl volume of fresh medium, which was then collected
for evaluation of basal CGRP and PGE2 release. Removed
medium was replaced by an equal volume of IS applied on
ganglia for further 5 minutes and also collected. Levels of
CGRP and PGE2 released by TG in medium were assessed
by EIA.
3.1. Effect of NSAIDs on CGRP Release from Trigeminal
Ganglia. Figure 1(a) reports the effect of oral administrationof NSAIDs at the dose of 10mg/Kg on CGRP release. During
the 5 minutes allowed for basal release, none of the drugs
used altered basal CGRP level detected in media, which
was 191± 12pg/ml medium (mean± SEM) for water-,
218± 21 pg/ml for nimesulide-, 162± 21.3 pg/ml for keto-
profen-, and 186± 13 pg/ml for etoricoxib-treated rats. In
the figure, CGRP levels are expressed as % of basal values
(measured before IS) that were normalised to 100. In vitro
addition of IS significantly increased CGRP released from
trigeminal ganglia. Thirty minutes after oral administra-
tion, only nimesulide was able to significantly decrease
the IS-stimulated levels of CGRP in comparison with con-
trols (water + IS). A partial inhibitory effect induced by
ketoprofen was also observed, since CGRP concentrations
were not anymore significantly different from basal levels,
although no difference was present in respect to CGRP
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Figure 2: (a) Effect of oral administration of 10mg/Kg nimesulide, ketoprofen, etoricoxib, or water on PGE2 release by trigeminal ganglia
both in basal condition and after in vitro stimulation with inflammatory soup (IS). Thirty minutes and 2 hours after administration, rats
were sacrificed, trigeminal ganglia were collected and maintained in vitro with DMEM alone for 5 minutes, then medium was collected,
and ganglia were stimulated with inflammatory soup for another 5 minutes. Values are mean± SEM of 6 animals; ∗∗∗p < 0,001 versus
water; °°p < 0,01; °°°p < 0,001 versus water + IS. (b) Dose-response curve of the inhibition by nimesulide, ketoprofen, and etoricoxib
treatments on in vitro basal and stimulated PGE2 releases by trigeminal ganglia. Rats were treated orally with NSAIDs at the doses of
10, 5, and 1mg/Kg. Two hours after administration, rats were sacrificed, trigeminal ganglia were collected and treated as in (a).
PGE2 release was measured in medium by EIA method. Values are mean± SEM of 6 animals ∗∗p < 0,01, ∗∗∗p < 0,001 versus water;°°p < 0,01; °°°p < 0,001 versus water + IS.
4 Mediators of Inflammationlevels measured in water-treated animals after stimulation
with IS. Two hours after in vivo drug administration,
nimesulide completely blocked the IS stimulation of
CGRP. At this time point also, ketoprofen was able to sig-
nificantly reduce, although not completely, the IS-induced
CGRP release. In contrast, no effect at any time point was
observed in etoricoxib-treated rats. Figure 1(b) reports the
effect of escalating doses of the NSAIDs on IS-stimulated
release, evaluated 2 hours after oral drug administration.
Nimesulide was able to reduce CGRP-stimulated release also
at 5mg/Kg, but at the lowest dose of 1mg/Kg, no significant
reduction was observed. The effect of ketoprofen was signif-
icant only at the dose of 10mg/Kg, while, as expected, etori-
coxib did not modulate CGRP release.3.2. Effect of NSAIDs on PGE2 Release from Trigeminal
Ganglia. Figure 2(a) shows basal- and IS-stimulated releases
of PGE2 from TG obtained 30 minutes and 2 hours after
administration of drugs at the dose of 10mg/Kg. Thirty
minutes after administration, nimesulide and ketoprofen sig-
nificantly reduced PGE2 basal release, while etoricoxib was
not effective. After IS stimulation, larger levels of PGE2 were
released from TG, and all the drugs tested were able to signif-
icantly reduce them. Two hours after drug administration,
TG isolated from rats treated with nimesulide, ketoprofen,
and etoricoxib released lower amounts of PGE2, both in
basal- and IS-stimulated conditions, in comparison with
water-treated animals. With regard to the dose-response
measured at 2 hours after treatment, ketoprofen significantly
5Mediators of Inflammationreduced both basal and stimulated PGE2 releases at all doses
tested (1, 5, and 10mg/Kg). The reduction induced by nime-
sulide was significant at 5 and 10mg/Kg both for basal- and
IS-activated releases, while etoricoxib significantly dimin-
ished PGE2 only at 10mg/Kg (Figure 2(b)).
4. Discussion
In this work, we demonstrate for the first time that in vivo
administration of nimesulide and ketoprofen inhibits stimu-
lated in vitro CGRP release from dissected rat TG. The data
described in this paper will contribute to the understanding
of the pharmacological mechanisms of the perhaps most fre-
quently used family of drugs in one of the most frequent
painful conditions in which they are employed. NSAIDs in
fact, despite the increasing use of the more recently intro-
duced triptans, remain the most commonly used for
migraine treatment, in particular for acute attacks, and they
offer the most cost-effective therapy showing only minor side
effects [17].
CGRP is known to play a key role in the pathophysiology
of migraine and other types of headaches by being released at
3 different sites by TG neurons: the afferent terminals that
innervate the meninges, the cell bodies in the ganglia, and
the afferent fibers that synapse in the spinal cord and core-
lease glutamate, CGRP, and other peptides. In our study,
we do not use cultured trigeminal cells, but dissected ganglia
that are only divided in 4 pieces to aid diffusion. This
approach allows the study of CGRP release from a TG
where all the indirect and direct interactions of neurons
with satellite cells are fundamentally maintained. More-
over, with this approach, the TG remain in vitro for a
maximum of 15 minutes, avoiding prolonged cell culturing
conditions that may affect the production and release of
CGRP. It has in fact been demonstrated that cell culturing
conditions can influence the expression and activity of
CGRP in TG neurons [18–20]. Other studies have recently
confirmed the advantage of using intact tissues, such as
brainstem explants, rather than isolated cells for testing
the effects of drugs on CGRP release in headache-related
studies [21].
In this study, CGRP and PGE2 releases were tested in
stimulated as well as basal conditions. Stimulation was used
to reproduce the sensitization of the trigeminal system which
is present in headache and migraine [22]. The IS employed to
mimic trigeminal sensitization consisted of bradykinin,
histamine, and serotonin, which are found to be released
endogenously during inflammation, and elevated potassium
and capsaicin were added to increase electrical activity, dur-
ing neurogenic inflammation [23–25]. In the present study,
NSAIDs are administered in vivo per os, in agreement with
the route of administration used for these drugs by patients.
The in vivo doses of nimesulide, ketoprofen, and etoricoxib
that we chose have been validated in several models of
inflammation and other pathological states in the rat, and
we believe that we are reproducing in our experimental
model the efficacious tissue level concentrations that are
reached in human subjects [14, 15, 26–32]. We demonstrate
that nimesulide and ketoprofen are able to reduce thestimulated release of CGRP from TG. We can therefore
hypothesize that after treatment with these NSAIDs, the
amount of CGRP available in the trigeminal vascular system
both centrally and peripherally is reduced, allowing less sen-
sitization and neurogenic inflammatory response. At the
highest dose (10mg/Kg), the inhibition induced by nimesu-
lide is complete, indicating that the drug can indeed prevent
the CGRP release. This effect is highly significant already at
30 minutes after oral administration, in line with the reported
evidence of the fast onset of action of nimesulide in patients
[16]. Interestingly, effective concentrations of nimesulide
can be detected both in plasma and synovial fluids 30min
after drug intake in patients with osteoarthritis [14].
Although NSAIDs have been used clinically for many years,
and it is well known that they share mechanisms that involve
inhibition of different cyclooxygenases, it is not clear what
other mechanisms are responsible for their different clinical
profiles, with special reference to their use in the treatment
of migraine. Experiments in rats or other animals as well as
in human biopsies suggest that PGE2 released from rat dura
mater upon electrical or chemical stimulations in vitro may
play an important role in the pathogenesis of migraine [17,
33]. As expected, all the NSAIDs that we tested were able to
rapidly inhibit both basal- and IS-stimulated PGE2 releases;
however, some differences emerged, as the nonselective
COX inhibitor ketoprofen reduced PGE2 release at the very
low dose of 1mg/Kg, the COX-2-selective etoricoxib was
active only at the higher dose of 10mg/Kg and the preferen-
tial COX-2 inhibitor nimesulide significantly reduced the
PGE2 release at the doses of 5 and 10mg/Kg. These observa-
tions suggest that both COX isoforms may be relevant in
PGE2 production in the TG. The modulation by COX inhib-
itors of CGRP release from TG has not been studied previ-
ously in sufficient depth; although in recent studies, it was
reported that COXs, and especially COX-2, may participate
in CGRP release from TG induced by inflammatory stimuli,
in different experimental models [13, 34–37]. Neeb et al.
[13] demonstrated that the COX-2 inhibitor parecoxib was
able to inhibit CGRP release from cultured trigeminal ganglia
cells, while in our study, the selective COX-2 inhibitor etori-
coxib was not effective. Several issues may explain this differ-
ence. Neeb et al. [13] added the NSAIDS directly on
trigeminal ganglia cultures, while we preferred to administer
them in vivo, in order to more closely mimic the clinical con-
dition. Moreover, a relevant difference is the duration of
stimulation. In our experiments, the IS was added only for
5 minutes, while Neeb et al. [13] demonstrated that a longer
time is needed in order to activate COX-2 synthesis. It can
therefore be hypothesized that mainly COX-1 may be
involved in the early phases of TG stimulation, while COX-
2 relevance is delayed. However, further experiments are
needed in order to assess this hypothesis. Our present results
indicate that the effect of NSAIDs on CGRP release in TG
may not be related only to their ability to decrease PGE2. In
fact, ketoprofen did not reduce CGRP release at doses of 1
and 5mg/Kg, while at the same doses, it was able to inhibit
PGE2 release, while etoricoxib at 10mg/Kg inhibited PGE2
release, but did not influence CGRP release. Of the 3 drugs
studied, nimesulide was the only NSAID able to reduce
6 Mediators of InflammationCGRP at the dose of 5mg/Kg; at this dose, nimesulide
induced a PGE2 inhibition that was similar to that of keto-
profen at the lowest dose at which no effect on CGRP was
observed. Moreover, while all drugs reduced PGE2 at the ear-
liest time tested (30 minutes after oral administration), only
nimesulide was able to modulate CGRP at this point in time.
Based on these evidences, it can be speculated that also other
different mechanisms, besides PGE2 inhibition, may be
involved in the effects of NSAIDs on CGRP release. This kind
of dissociation is particularly evident for nimesulide. These
results are in agreement with our previous data indicating
that nimesulide is more active than other NSAIDs in the
inhibition of stimulated substance P release from rat sensory
neurons and further confirm the multifactorial mode of
action of this NSAID [38–41]. The signals and mecha-
nisms governing the release of CGRP from sensory neurons
are not fully elucidated. Recently, it has been suggested that
CGRP release from TG takes place via two independent
mechanisms: a calcium/Snap 25-dependent as well as a
calcium-independent mechanism involving increases in
intracellular sodium ions and activation of the acid sensitive
ion channel ASIC3 [36]. It is interesting to note that many of
the proinflammatory mediators that promote and maintain
neurogenic inflammation within the dura mater have been
shown to stimulate expression and activity of these channels
and that NSAIDs at therapeutic doses inhibit ASIC channel
activity [42, 43]. More specific studies are necessary to iden-
tify the molecular mechanisms of the effects of nimesulide
and ketoprofen on CGRP release from TG.
5. Conclusions
The evaluation of basal and stimulated in vitro CGRP
release from rodent-isolated trigeminal ganglia is a reliable
method for the study of the effects of drugs used in the
treatment of migraine. The efficacy in reducing CGRP
release contributes a rationale for choosing a NSAID in
the treatment of migraine. The rapid onset of the effect
of nimesulide may explain the large use of this NSAID
by patients with migraine [44].
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